Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Metformin improves the angiogenic potential of human CD34+ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction

Fig. 1

Expression of pro-angiogenic factor VEGFA in CD34+ cell-derived conditioned media. The levels of VEGFA were assayed in three independent biological replicates using the MSD technique. Results are presented as ±SEM and were statistically analyzed using one-way ANOVA followed by Fisher’s LSD test. Data for effects of hypoxia and hyperglycemia were compared with control (5.5 mmol/L), and data for cells treated with metformin were compared with the corresponding metformin-untreated condition. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page